Literature DB >> 16056389

The ultimate model organism: progress in experimental medicine.

Bruce H Littman1, Stephen A Williams.   

Abstract

Experimental medicine is the use of innovative measurements, models and designs in studying human subjects for establishing proof of mechanism and concept of new drugs, for exploring the potential for market differentiation for successful drug candidates, and for efficiently terminating the development of unsuccessful ones. Humans are the ultimate 'model' because of the uncertain validity and efficacy of novel targets and drug candidates that emerge from genomics, combinatorial chemistry and high-throughput screening and the use of poorly predictive preclinical models. The in-depth investigation of the effects of drugs and the nature of disease progression is becoming ever more feasible because of advances in clinical biomarkers.

Entities:  

Mesh:

Year:  2005        PMID: 16056389     DOI: 10.1038/nrd1800

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  15 in total

1.  Recommended changes to oncology clinical trial design: revolution or evolution?

Authors:  Mark J Ratain; Rachel W Humphrey; Gary B Gordon; Gwen Fyfe; Peter C Adamson; Thomas R Fleming; Walter M Stadler; Donald A Berry; Carl C Peck
Journal:  Eur J Cancer       Date:  2007-11-05       Impact factor: 9.162

Review 2.  Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes.

Authors:  Rajesh Krishna; Gary Herman; John A Wagner
Journal:  AAPS J       Date:  2008-08-07       Impact factor: 4.009

3.  Microengineering methods for cell-based microarrays and high-throughput drug-screening applications.

Authors:  Feng Xu; JinHui Wu; ShuQi Wang; Naside Gozde Durmus; Umut Atakan Gurkan; Utkan Demirci
Journal:  Biofabrication       Date:  2011-07-01       Impact factor: 9.954

4.  Gain in Translation: Is It Time for Thigmotaxis Studies in Humans?

Authors:  Christian Grillon; Monique Ernst
Journal:  Biol Psychiatry       Date:  2016-09-01       Impact factor: 13.382

Review 5.  Clinical development of antiepileptic drugs in adults.

Authors:  Bernd Schmidt
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 6.  From bedside to bench and back again: research issues in animal models of human disease.

Authors:  Nancy C Tkacs; Hilaire J Thompson
Journal:  Biol Res Nurs       Date:  2006-07       Impact factor: 2.522

Review 7.  The impact of microfluidics in high-throughput drug-screening applications.

Authors:  Paola De Stefano; Elena Bianchi; Gabriele Dubini
Journal:  Biomicrofluidics       Date:  2022-05-26       Impact factor: 3.258

Review 8.  Removing obstacles in neuroscience drug discovery: the future path for animal models.

Authors:  Athina Markou; Christian Chiamulera; Mark A Geyer; Mark Tricklebank; Thomas Steckler
Journal:  Neuropsychopharmacology       Date:  2008-10-01       Impact factor: 7.853

Review 9.  The Nuremberg Code subverts human health and safety by requiring animal modeling.

Authors:  Ray Greek; Annalea Pippus; Lawrence A Hansen
Journal:  BMC Med Ethics       Date:  2012-07-08       Impact factor: 2.652

10.  Create a translational medicine knowledge repository--research downsizing, mergers and increased outsourcing have reduced the depth of in-house translational medicine expertise and institutional memory at many pharmaceutical and biotech companies: how will they avoid relearning old lessons?

Authors:  Bruce H Littman; Francesco M Marincola
Journal:  J Transl Med       Date:  2011-05-10       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.